Payment overview · 2025
General Payments
$5,684.31
252 reported records · 34 companies
Healthcare provider profile · identity verified
Jose R Baez, DO
Allopathic & Osteopathic Physicians|Internal Medicine · LAWRENCE, MA · NPI 1336103233
Verified facts
What the public records show
CMS Open Payments records show Jose R Baez, DO received $5,684.31 in general payments during 2025 across 252 reported records.
ABBVIE INC. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Eliquis, Entresto, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Ozempic, Prolia, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 550 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 509 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 1472 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 683 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,182.39 | 20.8% | 56 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $818.95 | 14.4% | 34 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $312.59 | 5.5% | 14 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $306.77 | 5.4% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $275.53 | 4.8% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $245.28 | 4.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $237.88 | 4.2% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $205.01 | 3.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $199.09 | 3.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $171.91 | 3.0% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $169.57 | 3.0% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $159.21 | 2.8% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $159.11 | 2.8% | 13 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $155.49 | 2.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $136.92 | 2.4% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $134.65 | 2.4% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $100.10 | 1.8% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $91.48 | 1.6% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.08 | 1.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.31 | 1.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.44 | 1.1% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $52.37 | 0.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $46.18 | 0.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.94 | 0.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.93 | 0.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.60 | 0.7% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $38.25 | 0.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.58 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.93 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.26 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.97 | 0.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.29 | 0.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.31 | 0.3% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.94 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,680.10 | 251 |
| Education | $4.21 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $587.00 | 23 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $529.36 | 23 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $529.36 | 23 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $456.25 | 24 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $312.59 | 14 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $306.77 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $275.53 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $245.28 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $205.01 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $202.15 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $199.09 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $196.78 | 9 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $169.57 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $155.49 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $143.88 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.08 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $138.40 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $136.92 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $135.54 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $134.65 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $123.11 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.25 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $100.10 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $98.90 | 5 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $98.04 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.70 | 6 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $76.81 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $68.08 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $66.30 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $65.65 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $65.65 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $65.65 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $63.31 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $62.44 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $52.37 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $46.18 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.93 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.58 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| THIRD WAVE Normalized: third wave |
Device | Hologic Sales and Service, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $7.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 60 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 68 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 247 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 127 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 1472 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 550 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 18 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 332 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
550 | 119 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
509 | 95 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
121 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
1472 | 248 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 36 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
247 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
60 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
332 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
683 | 126 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
127 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
247 | 42 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1900 | 362 |
| Omeprazole | Omeprazole | 1647 | 340 |
| Montelukast Sodium | Montelukast Sodium | 1619 | 304 |
| Farxiga | Dapagliflozin Propanediol | 1472 | 248 |
| Gabapentin | Gabapentin | 1407 | 286 |
| Metformin Hcl | Metformin Hcl | 1341 | 251 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 983 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 973 | 186 |
| Fluticasone Propionate | Fluticasone Propionate | 956 | 262 |
| Metoprolol Succinate | Metoprolol Succinate | 850 | 152 |
| Ezetimibe | Ezetimibe | 843 | 189 |
| Januvia | Sitagliptin Phosphate | 825 | 150 |
| Topiramate | Topiramate | 702 | 111 |
| Trulicity | Dulaglutide | 683 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 665 | 149 |
| Quetiapine Fumarate | Quetiapine Fumarate | 656 | 111 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 614 | 107 |
| Linzess | Linaclotide | 550 | 119 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 533 | 116 |
| Diclofenac Sodium | Diclofenac Sodium | 510 | 216 |
| Myrbetriq | Mirabegron | 509 | 95 |
| Meclizine Hcl | Meclizine Hcl | 502 | 107 |
| Lisinopril | Lisinopril | 441 | 102 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 440 | 81 |
| Alendronate Sodium | Alendronate Sodium | 427 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 424 | 73 |
| Mirtazapine | Mirtazapine | 406 | 77 |
| Finasteride | Finasteride | 385 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 79 |
| Glipizide Er | Glipizide | 382 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 64 |
| Potassium Chloride | Potassium Chloride | 337 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 332 | 65 |
| Fenofibrate | Fenofibrate Nanocrystallized | 312 | 55 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 301 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 275 | 47 |
| Lidocaine | Lidocaine | 273 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 271 | 51 |
| Furosemide | Furosemide | 258 | 46 |
| Allopurinol | Allopurinol | 248 | 35 |
| Eliquis | Apixaban | 247 | 42 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 244 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 59 |
| Irbesartan | Irbesartan | 241 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 237 | 46 |
| Losartan Potassium | Losartan Potassium | 231 | 55 |
| Raloxifene Hcl | Raloxifene Hcl | 228 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 227 | 37 |
| Memantine Hcl | Memantine Hcl | 221 | 46 |
| Famotidine | Famotidine | 207 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 204 | 35 |
| Trazodone Hcl | Trazodone Hcl | 202 | 40 |
| Vascepa | Icosapent Ethyl | 187 | 47 |
| Atenolol | Atenolol | 185 | 31 |
| Carvedilol | Carvedilol | 172 | 36 |
| Hydrocortisone | Hydrocortisone | 170 | 52 |
| Roflumilast | Roflumilast | 169 | 28 |
| Jardiance | Empagliflozin | 167 | 36 |
| Donepezil Hcl | Donepezil Hcl | 160 | 32 |
| Icosapent Ethyl | Icosapent Ethyl | 156 | 46 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 149 | 37 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 137 | 19 |
| Ozempic | Semaglutide | 135 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 132 | 59 |
| Entresto | Sacubitril/Valsartan | 127 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 125 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 21 |
| Brilinta | Ticagrelor | 121 | 23 |
| Sertraline Hcl | Sertraline Hcl | 121 | 25 |
| Tradjenta | Linagliptin | 118 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 65 |
| Dapagliflozin | Dapagliflozin Propanediol | 110 | 92 |
| Nystatin | Nystatin | 106 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 106 | 35 |
| Alcohol Pads | Alcohol Antiseptic Pads | 105 | 26 |
| Bupropion Xl | Bupropion Hcl | 103 | 19 |
| Simvastatin | Simvastatin | 100 | 25 |
| Xarelto | Rivaroxaban | 98 | 14 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 95 | 16 |
| Azithromycin | Azithromycin | 95 | 84 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 95 | 16 |
| Metformin Hcl Er | Metformin Hcl | 91 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 15 |
| Torsemide | Torsemide | 85 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 38 |
| Nifedipine Er | Nifedipine | 81 | 12 |
| Ciclopirox | Ciclopirox | 79 | 23 |
| Levofloxacin | Levofloxacin | 79 | 67 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 78 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 76 | 14 |
| Cefuroxime | Cefuroxime Axetil | 76 | 61 |
| Ketoconazole | Ketoconazole | 75 | 19 |
| Estradiol | Estradiol | 74 | 21 |
| Mounjaro | Tirzepatide | 74 | 20 |
| Buspirone Hcl | Buspirone Hcl | 73 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 15 |
| Creon | Lipase/Protease/Amylase | 68 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 17 |
| Levetiracetam | Levetiracetam | 66 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 63 | 18 |
| Gemtesa | Vibegron | 62 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 60 | 58 |
| Celecoxib | Celecoxib | 60 | 14 |
| Pregabalin | Pregabalin | 60 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 12 |
| Valacyclovir | Valacyclovir Hcl | 58 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 56 | 24 |
| Baclofen | Baclofen | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | suppressed |
| Trulance | Plecanatide | 53 | 11 |
| Cephalexin | Cephalexin | 52 | 48 |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | 12 |
| Ammonium Lactate | Ammonium Lactate | 51 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 50 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 13 |
| Ondansetron Odt | Ondansetron | 46 | 21 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 45 | 17 |
| Memantine Hcl Er | Memantine Hcl | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Spironolactone | Spironolactone | 44 | 11 |
| Lactulose | Lactulose | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Clonidine | Clonidine | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 36 |
| Prednisone | Prednisone | 40 | 26 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Nystop | Nystatin | 39 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 33 |
| Candesartan Cilexetil | Candesartan Cilexetil | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 20 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Mirabegron Er | Mirabegron | 35 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 35 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Sumatriptan | Sumatriptan | 34 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 29 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Rifampin | Rifampin | 28 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Tetracycline Hcl | Tetracycline Hcl | 20 | 20 |
| Tramadol Hcl | Tramadol Hcl | 20 | 11 |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | 17 |
| Belsomra | Suvorexant | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clarithromycin | Clarithromycin | 16 | 15 |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | 12 |
| Motegrity | Prucalopride Succinate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Calcitriol | Calcitriol | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Tinidazole | Tinidazole | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,684.31 · 252 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, CeQur Simplicity, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, SHINGRIX, THIRD WAVE, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, YUPELRI, ZAVZPRET, ZENPEP | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error